What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey

Int J Clin Oncol. 2022 Jul;27(7):1202-1211. doi: 10.1007/s10147-022-02168-y. Epub 2022 Apr 21.

Abstract

Objectives: To investigate the changes in epidemiological and survival characteristics of malignant mesothelioma (MM) cases diagnosed in a 30-year period between 1990 and 2019.

Methods: Data were analyzed considering three time periods (1990-1999, 2000-2009, 2010-2019) when treatment practices changed. The Join point Regression Program was used to analyze the change in clinical and epidemiological characteristics of the cases. Kaplan-Meier analysis was used to calculate the overall survival of the patients. Cox regression analysis was used to determine the effect of variables on survival.

Results: The study group consisted of 928 MM patients. During the study period, the mean age of the patients and the percentage of epithelioid subtype increased, while the percentage of female and histopathologically unidentified cases decreased. The median survival (95%CI) of patients according to the study periods was 9.0 (7.2-10.9), 9.0 (7.6-10.4) and 12.0 (10.5-13.5) months, respectively. A significant increase in overall survival was observed in the time trend (p = 0.013). There was no significant change in overall survival in patients receiving best supportive care over the 30-year period (p = 0.060), but an improvement of 1.4 (95%CI 0.2 to 2.7) months (p = 0.027) was observed in patient receiving chemotherapy. An improvement in overall survival of 4.8 (1.2 to 8.4) months was also observed in patients receiving multimodality treatment during 2000-2019 (p = 0.014). MM patients who were younger, female, diagnosed after 2000, epithelioid subtype, early stage, and received chemotherapy or multimodal treatment had longer survival.

Conclusions: It was found that histopathological diagnosis and treatment success in MM have improved over the years.

Keywords: Chemotherapy; Histopathological diagnosis; Join point regression analysis; Malignant mesothelioma; Multimodality treatment.

MeSH terms

  • Female
  • Humans
  • Mesothelioma* / drug therapy
  • Mesothelioma* / epidemiology
  • Mesothelioma, Malignant*
  • Pleural Neoplasms* / drug therapy
  • Survival Rate
  • Turkey / epidemiology